Polycystic Liver Disease: Causes, Symptoms, and Treatments

Polycystic liver disease is a genetic condition in which dozens to hundreds of fluid-filled cysts develop throughout the liver, sometimes enlarging it to several times its normal size. Most people who have it never know, because the cysts stay small and cause no trouble. But in roughly two to five percent of cases, the liver grows large enough to cause pain, compress nearby organs, and seriously erode quality of life.¹ Understanding the genetic roots, the role hormones play, and the range of treatments available helps make sense of a disease that can look wildly different from one person to the next.

The Genetic Roots

Polycystic liver disease (PLD) falls into two broad categories depending on which gene mutations are involved. The more common scenario is liver cysts that develop alongside polycystic kidney disease, driven by mutations in the PKD1 or PKD2 genes. In those cases, the kidneys are the primary target, and the liver cysts come along for the ride. Roughly 85 percent of genetically resolved polycystic kidney disease traces to PKD1, with most of the remainder linked to PKD2.²

The second category is isolated polycystic liver disease, where the kidneys are largely spared and the liver bears the full brunt. This form is caused by a different set of mutations, primarily in genes called PRKCSH, SEC63, and LRP5.² These genes code for proteins involved in processing and transporting other proteins inside the cells that line bile ducts. When those proteins malfunction, the bile-duct cells start growing and secreting fluid in ways they normally would not, eventually forming cysts.³

Both forms follow an autosomal dominant inheritance pattern, which means inheriting just one copy of a mutated gene from either parent is enough to develop the disease. A Portuguese autopsy study looking at over 31,000 cases found isolated PLD in about 0.18 percent and PLD coexisting with polycystic kidneys in 0.04 percent. Only about 16 percent of PLD cases in that study occurred alongside polycystic kidney disease, reinforcing that isolated PLD is its own distinct entity rather than simply a byproduct of kidney disease.⁴

How Cysts Grow and Why Estrogen Matters

The cysts in PLD are lined by cells derived from bile ducts, called cholangiocytes. In normal bile ducts, certain signaling molecules keep cell growth in check and regulate how much fluid gets secreted into the duct. In PLD, the mutated proteins disrupt calcium levels inside these cells, which in turn ramps up a signaling molecule called cAMP. Higher cAMP drives the cells to multiply faster and pump more fluid into the cyst lumen, inflating the cysts like tiny balloons.⁵ Those cyst-lining cells also actively secrete chloride and absorb sodium, creating an osmotic gradient that pulls water into the cyst and keeps it expanding.⁶

Estrogen plays a major amplifying role. Female sex is the single most important risk factor for both developing symptomatic PLD and for the disease being more severe. Cystic cholangiocytes carry estrogen receptors, and exposing them to estrogen increases their growth rate in laboratory experiments.⁷ Clinical data backs this up: in postmenopausal women with polycystic kidney disease, estrogen therapy was associated with about a seven percent increase in total liver volume over the study period, while women not on estrogen saw their livers stay stable or shrink slightly.⁸ After menopause, when estrogen levels drop naturally, liver growth tends to slow down.⁷ This hormonal link is one reason PLD is often more clinically significant in women than in men, even though the underlying genetic mutations occur at similar rates in both sexes.

Symptoms and Who Gets Them

Most people with PLD live their whole lives without meaningful symptoms. The liver has an enormous functional reserve, and even a liver studded with cysts can do its job perfectly well. Liver enzymes and standard liver function tests usually come back normal or near-normal, which is part of why the disease often gets picked up incidentally on an imaging scan ordered for something else entirely.⁹

Trouble starts when the liver gets big enough to crowd other organs. In advanced disease, patients can develop massively enlarged livers that produce a spectrum of complaints.¹⁰ The most common symptoms include:

Abdominal pain: dull, chronic pain in the upper abdomen, often worse after meals.
Abdominal distension: a visibly swollen belly that can be mistaken for weight gain or pregnancy.
Early fullness: the enlarged liver compresses the stomach, making it hard to eat a normal-sized meal.
Shortness of breath: upward pressure on the diaphragm can make breathing feel labored, especially when lying flat.
Back pain: the sheer weight and size of the liver can strain the spine and surrounding muscles.

A quality-of-life study found that PLD patients scored significantly lower than the general population on measures of physical functioning, general health, vitality, and social functioning. Upper and lower abdominal pain and breathlessness were the symptoms most strongly tied to reduced physical well-being.¹¹ Mental health scores, interestingly, were comparable to the general population, suggesting that the burden of PLD is overwhelmingly physical rather than psychological.¹¹

Complications Beyond Size

Aside from the mechanical problems caused by sheer liver volume, individual cysts can develop their own complications. Cyst infection is the most clinically worrying of these and can present with fever, localized pain, and elevated inflammatory markers. Bleeding inside a cyst (intracystic hemorrhage) can cause sudden, sharp pain. More rarely, a cyst on a stalk can twist on itself, or a cyst near the liver surface can rupture.¹² Treatment for these acute events depends on severity: infected cysts usually require antibiotics and sometimes drainage, while a ruptured cyst may need percutaneous drainage or, in serious cases, surgery.¹³

Some patients with very advanced disease develop portal hypertension, where the cysts compress blood vessels within the liver enough to raise pressure in the portal venous system. This can lead to fluid buildup in the abdomen (ascites) and other vascular complications typically associated with cirrhosis, even though the liver cells themselves are functioning normally. It is worth stressing that PLD is not a cancer risk the way some other liver conditions are. The cysts are benign growths of bile-duct lining, not tumors.

Conditions That Mimic PLD

Not every liver full of cysts is polycystic liver disease. Simple congenital cysts are extremely common and usually appear as one or a few isolated fluid pockets. Biliary hamartomas, sometimes called von Meyenburg complexes, are clusters of tiny cysts derived from embryonic bile ducts that can look worrying on imaging but are almost always harmless. Caroli disease is a rarer autosomal recessive condition that causes ballooning of the larger bile ducts; unlike PLD cysts, Caroli disease carries a meaningful risk of developing into bile-duct cancer.¹⁴ The diagnostic threshold for PLD is generally set at 20 or more cysts scattered through the liver, with a family history or genetic confirmation helping to distinguish it from other cystic conditions.

Drug Treatment With Somatostatin Analogues

Because elevated cAMP drives cyst growth and fluid secretion, researchers have focused on drugs that reduce cAMP levels in bile-duct cells. Somatostatin analogues, originally developed for conditions like acromegaly, do exactly that. The two most studied are octreotide and lanreotide, both given as long-acting injections, typically once a month.

In individual trials, the results are encouraging but modest. One crossover trial of octreotide found that liver volume shrank by an average of about 71 milliliters during the treatment period, while it crept up by 14 milliliters during placebo.¹⁵ A larger trial of lanreotide followed patients for about two and a half years and found that liver volume shrank by roughly two percent in the treatment group but grew by about four percent in the control group, a net difference of about six percent.¹⁶ Four months after patients stopped lanreotide, some of the benefit was still measurable, suggesting the drug does more than just temporarily suppress fluid secretion.¹⁶

When the data from multiple randomized trials are pooled, though, the overall difference in liver volume between somatostatin analogues and placebo did not reach statistical significance, with an average reduction of about 176 milliliters that could plausibly be due to chance.¹⁷ That gap between individual trial results and pooled analysis is a reminder that somatostatin analogues slow liver growth rather than dramatically shrink it. They are most useful for patients whose disease is progressing but who are not yet sick enough for surgery, essentially buying time and limiting the pace of enlargement.

Aspiration Sclerotherapy for Dominant Cysts

When symptoms are driven by one or a few especially large cysts rather than by the liver as a whole, a less invasive procedure called aspiration sclerotherapy can help. A needle is inserted through the skin under imaging guidance, the cyst fluid is drained, and a sclerosing agent (usually ethanol) is injected to damage the cyst lining and discourage re-accumulation. In one study, this approach reduced liver volume by an average of about 17 to 19 percent.¹⁸ A systematic review found excellent long-term efficacy and safety for simple hepatic cysts, though the authors cautioned that the quality of available studies makes definitive conclusions difficult.¹⁹

The limitation of aspiration sclerotherapy is that it targets individual cysts. In a liver packed with hundreds of cysts, draining one or two may not make a meaningful dent in overall liver size. It works best when the symptom burden comes from a specific dominant cyst that is compressing the stomach, diaphragm, or other structures.

Surgery for Severe Disease

For patients with massive hepatomegaly who are too symptomatic to manage conservatively, the main surgical option is partial hepatectomy combined with cyst fenestration. The surgeon removes the most affected portion of the liver and opens (fenestrates) remaining cysts so they drain into the abdominal cavity, where the fluid gets reabsorbed. It is aggressive but effective: one study of selected patients found a median liver volume reduction of 61 percent after the procedure, dropping from a median of about 6,800 milliliters down to around 2,500 milliliters, and that reduction was sustained over long-term follow-up.²⁰

Other surgical series confirm that the procedure provides durable symptom relief and sustained reductions in liver size, though the morbidity rate is significant, meaning complications like bile leaks, infections, and the need for blood transfusions are not uncommon.²¹ This is not a procedure taken lightly. Guidelines generally reserve it for patients with severe symptoms like pain, inability to eat, weight loss, or breathing difficulty, and for whom less invasive options have failed or are unsuitable.²²

Liver Transplantation

In the most extreme cases, when the liver is so massively enlarged that no partial resection would leave enough healthy tissue, or when complications like portal hypertension set in, liver transplantation becomes the definitive treatment. In an Ontario cohort, about three-quarters of PLD patients who received a transplant did so because of debilitating symptoms from sheer mass effect, while roughly 16 percent had developed portal hypertensive complications. After a median follow-up of over six years, patient survival was 96 percent.²³

PLD patients face a particular challenge in the transplant system: because their livers function normally by standard lab tests, they often score lower on allocation models that prioritize liver failure. A large retrospective study found that PLD patients waited an average of 508 days for a transplant, compared to 154 days for patients transplanted for other indications. The silver lining is that outcomes after transplant are very good. Five-year patient survival was about 81 percent for PLD, compared to roughly 77 percent for non-PLD recipients, and graft survival showed a similar advantage.²⁴ The likely explanation is that PLD patients tend to be otherwise healthier than people transplanted for cirrhosis or cancer, giving them a better baseline going into surgery.

Nutrition, Malnutrition, and Practical Management

One of the underappreciated consequences of severe PLD is malnutrition. When the liver takes up most of the abdomen, it physically compresses the stomach and intestines, making it hard to eat normal portions. Patients often lose weight and, more worryingly, lose muscle mass. A study of patients treated with lanreotide found that even though subjects reported better food intake while on the drug, they still lost an average of two kilograms of body weight and measurable muscle mass over the treatment period.²⁵

Nutritional guidance for PLD centers on eating smaller, more frequent meals to work around the limited stomach capacity, and ensuring enough protein to protect muscle. When sarcopenia starts to appear, protein intake may need to be increased to roughly 1.2 to 1.5 grams per kilogram of body weight per day.²⁶ Adequate calorie intake matters too, since the combination of reduced appetite and increased metabolic demand from the enlarged liver can create a caloric deficit that accelerates muscle loss. There is no specific diet proven to slow cyst growth, but avoiding estrogen-containing supplements and oral contraceptives is generally advised given estrogen’s role in driving liver enlargement.

PLD in Children

Polycystic liver disease is overwhelmingly a condition of adulthood, with cysts typically becoming detectable on imaging in the third or fourth decade of life and symptoms, when they occur, peaking later. Pediatric cases of isolated PLD are extremely rare and make the medical literature mainly as case reports.³ When PLD-like liver cysts appear in a child, clinicians typically look carefully for an underlying recessive condition like autosomal recessive polycystic kidney disease or Caroli disease rather than assuming it is the dominant adult form. Genetic testing has become increasingly important in these cases, since knowing whether the mutations are in the PRKCSH/SEC63 family or the PKD1/PKD2 family changes both the prognosis and the monitoring plan.

How Prevalence Numbers Can Be Misleading

Estimates of how common PLD is vary widely depending on how you look and whom you study. The Portuguese autopsy data put isolated PLD at about 0.18 percent of the population.⁴ A population-based study in Olmsted County, Minnesota, calculated the prevalence of definite or likely autosomal dominant PLD at roughly 10 per 100,000, while including possible cases pushed that figure closer to 36 per 100,000.²⁷ The gap between these numbers comes down to methods: autopsies catch cysts that were never noticed during life, while clinical registries catch only cases that come to medical attention. Neither number captures the full picture, and the true prevalence of having the mutation is almost certainly higher than the rate of diagnosis, since most carriers never develop symptoms worth investigating.

This matters practically because family members of someone diagnosed with PLD sometimes wonder whether they should be screened. Current clinical practice does not generally recommend screening asymptomatic relatives the way it does for polycystic kidney disease, partly because PLD without kidney involvement rarely threatens organ function and there is no preventive treatment proven to change outcomes if you catch it early. If a family member develops symptoms or is found to have multiple liver cysts incidentally, genetic counseling and targeted imaging can clarify the picture.

1
PubMed Central. Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment
2
PubMed Central. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease
3
PubMed Central. Isolated polycystic liver disease in a child
4
Liver International Communications. Epidemiological Insights Into Polycystic Liver Disease: Data From Forensic Autopsies in Portugal
5
PubMed Central. Polycystic Liver Diseases: Congenital Disorders of Cholangiocyte Signaling
6
PubMed. Regulated ion transport in mouse liver cyst epithelial cells
7
PubMed Central. Estrogens in polycystic liver disease: A target for future therapies?
8
PubMed. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease
9
Annals of Hepatology. Polycystic liver disease: a clinical review
10
PubMed Central. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management
11
PubMed. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume
12
PubMed Central. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases
13
PubMed Central. Complications arising in simple and polycystic liver cysts
14
Journal of Clinical and Translational Hepatology. Differentiating Cystic Liver Lesions: A Review of Imaging Modalities, Diagnosis and Management
15
PubMed Central. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide
16
Gastroenterology. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease
17
Scientific Reports. The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
18
PubMed Central. Aspiration–sclerotherapy Results in Effective Control of Liver Volume in Patients with Liver Cysts
19
PubMed. Efficacy and Safety of Aspiration Sclerotherapy of Simple Hepatic Cysts: A Systematic Review
20
PubMed Central. Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease
21
PubMed. Partial major hepatectomy with cyst fenestration for polycystic liver disease: Indications, short and long-term outcomes
22
PubMed. Treatment of polycystic liver disease. Update on the management
23
PubMed Central. Liver transplantation in adult polycystic liver disease: the Ontario experience
24
PLOS ONE. Liver transplant recipients with polycystic liver disease have longer waiting times but better long-term clinical outcomes than those with liver disease due to other causes: A retrospective cross-sectional study
25
PubMed. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease
26
PubMed Central. Key Aspects in the Nutritional Management of Polycystic Liver Disease Patients
27
JHEP Reports. Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county